Marpai (MRAI) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
13 Aug, 2026Executive summary
Revenue for Q2 2026 was $4.2M, down 10.5% year-over-year, primarily due to customer turnover.
Net loss for Q2 2026 was $4.6M, a 4.9% increase from Q2 2025; net loss for the first half of 2026 was $7.8M.
The company continues to focus on technology-driven TPA services for self-insured employers and is adapting to evolving market needs.
Financial highlights
Q2 2026 revenue: $4.2M (Q2 2025: $4.7M); H1 2026 revenue: $8.6M (H1 2025: $10.1M).
Q2 2026 operating loss: $3.4M; H1 2026 operating loss: $5.9M.
Q2 2026 net loss per share: $(0.18); H1 2026 net loss per share: $(0.31).
Cost of revenue decreased year-over-year, reflecting lower sales volume.
Interest expense increased due to non-cash adjustments related to the AXA obligation.
Outlook and guidance
Management projects the need for additional capital to fund operations until revenue scales to self-sufficiency.
Ongoing evaluation of funding alternatives, including equity, debt, or asset sales.
Substantial doubt exists about the company's ability to continue as a going concern over the next 12 months.
Latest events from Marpai
- Q1 2026 saw revenue drop 18% and a net loss of $3.2M, with urgent liquidity and debt restructuring.MRAI
Q1 2026 - Revenue declined 36% and net loss improved, but liquidity and going concern risks remain acute.MRAI
Q4 2025 - Board seeks approval for director elections, auditor ratification, and preferred stock authorization.MRAI
Proxy Filing - Shareholders will vote on director elections, auditor ratification, and preferred stock authorization.MRAI
Proxy Filing - Facing ongoing losses and liquidity risks, the company relies on new capital to sustain operations.MRAI
Registration Filing - Q2 2025 saw revenue drop but major cost cuts, with profitability targeted for early 2026.MRAI
Q2 2025 - Q3 2024 losses narrowed as cost cuts and investments offset revenue decline and liquidity risks.MRAI
Q3 2024 - Q2 2024 saw a 28% revenue drop, $13M net loss, and a $7.6M impairment charge.MRAI
Q2 2024 - Losses narrowed in 2024; new PBM products and partnerships target 2025 profitability.MRAI
Q4 2024